WO2007013041A3 - Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases - Google Patents

Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases Download PDF

Info

Publication number
WO2007013041A3
WO2007013041A3 PCT/IB2006/052578 IB2006052578W WO2007013041A3 WO 2007013041 A3 WO2007013041 A3 WO 2007013041A3 IB 2006052578 W IB2006052578 W IB 2006052578W WO 2007013041 A3 WO2007013041 A3 WO 2007013041A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiac
natriuretic peptide
inactive
managment
monitoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/052578
Other languages
French (fr)
Other versions
WO2007013041A2 (en
Inventor
Jens-Peter Seher
Malcolm G Pluskal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips Electronics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics NV filed Critical Koninklijke Philips Electronics NV
Priority to JP2008523521A priority Critical patent/JP5090348B2/en
Priority to US11/996,810 priority patent/US20080221033A1/en
Priority to EP06780226.4A priority patent/EP1913402B1/en
Priority to ES06780226.4T priority patent/ES2657087T3/en
Publication of WO2007013041A2 publication Critical patent/WO2007013041A2/en
Publication of WO2007013041A3 publication Critical patent/WO2007013041A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

In a cardiac monitoring method, at least an inactive natriuretic peptide (22) and an active natriuretic peptide (20) are assayed in a biological sample taken from a patient. Both the inactive and active natriuretic peptides are produced in the patient responsive to cardiac stress. A therapeutic agent (26), such as a synthetic or mimetic natriuretic peptide, is administered to the patient. The administered therapeutic agent substantially interferes with the active natriuretic peptide assay but does not substantially interfere with the inactive natriuretic peptide assay. Kinetics of the administered therapeutic agent are determined based on at least the active natriuretic peptide assay. Cardiac diagnostic information is determined based on at least the inactive natriuretic peptide assay.
PCT/IB2006/052578 2005-07-29 2006-07-27 Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases Ceased WO2007013041A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2008523521A JP5090348B2 (en) 2005-07-29 2006-07-27 Monitoring of cardiac natriuretic peptide during diagnosis, treatment and treatment of heart disease
US11/996,810 US20080221033A1 (en) 2005-07-29 2006-07-27 Monitoring of Cardiac Natriuretic Peptides During Diagnosis, Management, and Treatment of Cardiac Diseases
EP06780226.4A EP1913402B1 (en) 2005-07-29 2006-07-27 Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases
ES06780226.4T ES2657087T3 (en) 2005-07-29 2006-07-27 Monitoring of cardiac natriuretic peptides during diagnosis, management and treatment of heart disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70392805P 2005-07-29 2005-07-29
US60/703,928 2005-07-29

Publications (2)

Publication Number Publication Date
WO2007013041A2 WO2007013041A2 (en) 2007-02-01
WO2007013041A3 true WO2007013041A3 (en) 2007-10-11

Family

ID=37683727

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/052578 Ceased WO2007013041A2 (en) 2005-07-29 2006-07-27 Monitoring of cardiac natriuretic peptides during diagnosis, managment, and treatment of cardiac diseases

Country Status (6)

Country Link
US (1) US20080221033A1 (en)
EP (1) EP1913402B1 (en)
JP (1) JP5090348B2 (en)
CN (1) CN101233411A (en)
ES (1) ES2657087T3 (en)
WO (1) WO2007013041A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
DE102007021443A1 (en) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnosis and risk stratification using NT-proET-1
EP2467719A4 (en) * 2009-08-19 2013-01-09 Marker detection for characterizing the risk of cardiovascular disease or complications thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4415896A1 (en) * 1994-05-05 1995-11-09 Boehringer Mannheim Gmbh Analysis system for monitoring the concentration of an analyte in the blood of a patient
US7632647B2 (en) * 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
CN1185493C (en) * 2001-11-16 2005-01-19 清华大学 Intelligent microdestructive blood sugar tester measuring method and devcie
WO2003079979A2 (en) * 2002-03-18 2003-10-02 Scios Inc. Method for treating congestive heart failure
WO2004046729A2 (en) * 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
CA2535971C (en) * 2003-08-20 2018-04-10 Biosite, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
US7632234B2 (en) * 2003-08-29 2009-12-15 Medtronic, Inc. Implantable biosensor devices for monitoring cardiac marker molecules
GB0329288D0 (en) * 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
JP2007534363A (en) * 2003-12-18 2007-11-29 インバーネス メディカル スウィッツァーランド ゲーエムベーハー Monitoring method and monitoring apparatus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURGER ANDREW J ET AL: "Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study.", AMERICAN HEART JOURNAL, vol. 144, no. 6, December 2002 (2002-12-01), pages 1102 - 1108, XP002427034, ISSN: 0002-8703 *
GEGENHUBER ALFONS ET AL: "Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure.", CLINICAL CHEMISTRY FEB 2004, vol. 50, no. 2, February 2004 (2004-02-01), pages 454 - 456, XP002427032, ISSN: 0009-9147 *
RADEMAKER M T ET AL: "CARDIAC NATRIURETIC PEPTIDES FOR CARDIAC HEALTH", CLINICAL SCIENCE, BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, vol. 108, no. 1, January 2005 (2005-01-01), pages 23 - 36, XP009060567, ISSN: 0143-5221 *
RICHARDS MARK ET AL: "NT-proBNP in heart failure: therapy decisions and monitoring.", EUROPEAN JOURNAL OF HEART FAILURE : JOURNAL OF THE WORKING GROUP ON HEART FAILURE OF THE EUROPEAN SOCIETY OF CARDIOLOGY 15 MAR 2004, vol. 6, no. 3, 15 March 2004 (2004-03-15), pages 351 - 354, XP002427033, ISSN: 1388-9842 *

Also Published As

Publication number Publication date
JP2009503490A (en) 2009-01-29
WO2007013041A2 (en) 2007-02-01
EP1913402A2 (en) 2008-04-23
ES2657087T3 (en) 2018-03-01
EP1913402B1 (en) 2017-10-25
JP5090348B2 (en) 2012-12-05
CN101233411A (en) 2008-07-30
US20080221033A1 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
WO2004103150A3 (en) Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin
WO2006009702A3 (en) Liver disease-related methods and systems
US20220241028A1 (en) Prediction of blood perfusion difficulties based on biomarker monitoring
WO2008055491A3 (en) Diagnosis and risk assessment of pancreatic diabetes using mr-proadm
WO2007001342A3 (en) Exhaled breath condensate collection and assay system and method
WO2005121788A3 (en) Method for the early detection of renal disease and injury
WO2007006858A3 (en) Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
WO2003009806A3 (en) Methods for evaluating pathologic conditions using extracellular rna
WO2003096164A3 (en) Medical information system
WO2002014537A3 (en) Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
EP2008581A3 (en) Patient monitoring, diagnosis, and/or therapy systems and methods
DE602007000529D1 (en) Active medical implant, in particular device for stimulation, resynchronization, defibrillation and / or cardioversion, comprising means for predictive warning of an exacerbation of the disease state of the patient
BR0111473A (en) Methods for screening an individual for glycogen storage disease, for screening an individual for pomp disease, for monitoring the clinical condition of an individual with pomp disease, to estimate the efficacy of a therapeutic regimen for an individual with disease pompe and to determine the concentration of an oligosaccharide in a biological sample
ATE435657T1 (en) THERAPEUTIC PREPARATION OF HIGHLY PURE FVIIA AND METHOD FOR OBTAINING IT
WO2003048775A3 (en) Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
WO2005026687A3 (en) Diagnosis and monitoring of hepatocellular carcinoma
WO2006025028A3 (en) Novel classification method of blood cells and tailor-made therapy and prevention based thereupon
WO2005098429A3 (en) System and method for real-time diagnosis, treatment, and therapeutic drug monitoring
TW200622245A (en) Abnormalities of phosphatase 2A (PP2A) for diagnosis and treatment of alzheimer's disease
WO2000066782A3 (en) Diagnostic assay for diabetes mellitus based on mutational burden
WO2003024324A3 (en) METHODS FOR IN VIVO EVALUATION OF A PHYSIOLOGICAL STRUCTURE OR FUNCTION USING POLARIZED129Xe
WO2003034072A3 (en) Diagnosis and therapy of conditions involving alms1
BR0318166A (en) use of a sgk1 detection substance, detection kit, as well as a pharmaceutical composition that inhibits or activates its expression and / or function
WO2007103303A3 (en) Systems and methods using a dynamic expert system to provide patients with aesthetic improvement procedures
Beniwal et al. SpO2/FiO2 and PaO2/FiO2 for Predicting Intensive Care Admission in Wheezy Children: An Observational Study

Legal Events

Date Code Title Description
REEP Request for entry into the european phase

Ref document number: 2006780226

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006780226

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008523521

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11996810

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 200680027919.3

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 936/CHENP/2008

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2006780226

Country of ref document: EP